WHO Urges Strict Clinical Trials for Ebola Treatments and Vaccines Amid Deadly Bundibugyo Outbreak

GENEVA — The World Health Organization (WHO) issued an urgent directive on May 28, 2026, mandating that all candidate therapeutics and vaccines for the current Bundibugyo Ebola outbreak be evaluated exclusively within controlled clinical trials. The decision marks a critical turning point in international efforts to contain the escalating crisis in East and Central Africa, which was declared a Public Health Emergency of International Concern (PHEIC) earlier this month. As the virus spreads across borders, global health authorities are striving to balance the desperate need for patient care with the rigorous scientific standards required to find a proven cure.

The announcement comes as the outbreak, which originated in the Democratic Republic of the Congo (DRC), continues to surge rapidly. Epidemiological data indicates over 1,000 suspected cases and nearly 250 deaths across multiple Congolese provinces. The virus has also crossed into neighboring Uganda, which has confirmed seven cases and one fatality.

The Core Challenge: No Approved Tools for Bundibugyo

A primary driver behind the WHO’s strict directive is a sobering scientific reality: there are currently no licensed treatments or vaccines approved specifically for the Bundibugyo species of the Ebola virus.

This creates a starkly different clinical environment compared to recent outbreaks involving the more common Zaire Ebola strain. For the Zaire variant, healthcare workers rely on Merck’s licensed Ervebo vaccine and established monoclonal antibody therapies. However, data regarding Ervebo’s effectiveness against the Bundibugyo strain remains limited and inconclusive, meaning health professionals are essentially operating without a validated pharmaceutical toolkit.

Despite this gap, a WHO expert advisory group has prioritized several experimental candidates for rapid clinical evaluation:

Priority Therapeutics for Infected Patients

• MBP134 (Mapp Biopharmaceutical): A monoclonal antibody cocktail that has demonstrated strong efficacy in animal models.

• Maftivimab (Regeneron): An antibody drug that has shown neutralizing activity against the Bundibugyo virus in laboratory tests.

• Remdesivir (Gilead Sciences): A broad-spectrum antiviral drug that is already physically available within the DRC for other therapeutic uses.

Priority Preventative Interventions

• Obeldesivir (Gilead Sciences): An experimental oral antiviral being highlighted for post-exposure prophylaxis to protect high-risk contacts.

• ChAdOx1 Bundibugyo (Oxford University/Serum Institute of India): A vaccine candidate that could be ready for field testing within two to three months, pending the finalization of animal safety data.

• rVSV Bundibugyo (International AIDS Vaccine Initiative): A promising single-dose vaccine candidate, though current manufacturing timelines mean it is unlikely to be ready for trial deployment for another seven to nine months.

Balancing Emergency Urgency with Scientific Rigor

The mandate to restrict these experimental therapies to clinical trials highlights a perennial dilemma in bioethics: how to ethically distribute unproven medicines during a deadly epidemic.

Dr. Katherine Seethorthy, who leads the WHO’s research and development initiatives, emphasized the logistical and scientific hurdles during a Geneva press conference. Referring to the most promising single-dose vaccine candidate, she noted that no immediate doses are available for deployable clinical trials. “Our information indicates that this process is likely to take six to nine months,” Seethorthy stated, underscoring the reality that a preventative vaccine will not serve as an immediate silver bullet for the current surge.

Independent experts agree that scientific discipline must be maintained, even under emergency conditions. Dr. Thomas Geisbert, a leading virologist at the University of Texas Medical Branch in Galveston who is not involved in the WHO mandate, provided crucial context on the therapeutic potential of the antibody cocktail MBP134. His research team previously reported that MBP134 resulted in significant recovery in five out of six non-human primates infected with the Bundibugyo virus after they began showing advanced symptoms, such as fever.

“It’s a genuine therapeutic — we’ve utilized it against Bundibugyo, and it performs exceedingly well, even when patients are quite ill,” Geisbert stated. He added that evaluating both MBP134 and remdesivir in tandem during this outbreak is a highly sensible approach.

Furthermore, supply chain readiness will dictate how quickly these trials can begin. Larry Zeitlan, CEO of Mapp Biopharmaceutical, confirmed that the company maintains sufficient stockpiles of MBP134 to support the upcoming trials. The therapeutic supply is currently owned by the United States government’s Biomedical Advanced Research and Development Authority (BARDA), which is coordinating with international agencies for potential deployment.

Outbreak Context and Statistical Reality

This crisis represents the 17th Ebola outbreak recorded in the DRC, but it is uniquely dangerous because it is the first time the Bundibugyo species has emerged in this specific region. The species was first identified in 2007 in Uganda and historically carries a case fatality rate of 30% to 50%, making it less lethal than the Zaire strain (which can exceed 60% to 80% mortality) but still exceptionally severe.

The current outbreak was formally verified on May 15, 2026, when the Institut National de Recherche Biomédicale (INRB) in Kinshasa analyzed 13 blood samples from the Rwampara Health Zone in Ituri Province, finding eight positive matches for Bundibugyo.

Current Bundibugyo Outbreak Status (as of late May 2026)

The rapid geographical expansion prompted WHO Director-General Dr. Tedros Adhanom Ghebreyesus to officially declare the event a Public Health Emergency of International Concern on May 17, 2026.

What This Means for Public Health and Daily Protection

For healthcare professionals, humanitarian workers, and communities in East and Central Africa, the absence of an immediate, off-the-shelf vaccine means that classic public health interventions remain the primary line of defense.

Dr. Tedros stressed that international and local teams must rely on the traditional containment mechanisms that have successfully stopped past Ebola outbreaks. These include rigorous disease surveillance, rapid diagnostic testing, exhaustive contact tracing, patient isolation, and robust infection prevention controls within clinics. Engaging local communities to ensure safe and dignified burials is also paramount to preventing transmission from deceased individuals.

Traditional Containment Strategies:
[Surveillance & Testing] ➔ [Contact Tracing] ➔ [Isolation & Clinical Care] ➔ [Community Engagement]

The WHO has explicitly advised against international travel or trade restrictions, maintaining that closing borders does not effectively restrict viral transmission and often severely damages local economies and healthcare supply chains. However, regional risk remains highly elevated. Because the affected zones feature high population mobility, fluid trade networks, and cross-border travel between the DRC, Uganda, and other neighboring states, local clinicians must remain on high alert for patients presenting with sudden fever and hemorrhagic symptoms.

Tragically, the outbreak has already exacted a heavy toll on frontline medical personnel. At least four deaths have been reported among healthcare workers whose clinical symptoms strongly suggested viral hemorrhagic fever. These losses underscore persistent gaps in personal protective equipment (PPE) and highlight the extreme risk of healthcare-associated transmission when a virus remains unrecognized in a clinic.

Limitations, Uncertainties, and Next Steps

Global health experts acknowledge that current figures likely represent only the tip of the iceberg. The high positivity rate among initial blood samples, combined with confirmed urban cases in Kampala and rising syndromic reports, suggests that surveillance systems are lagging behind the actual spread. Epidemiological modeling from Imperial College London indicates that the true burden of the disease may already exceed 1,000 active cases in the region.

Because using experimental drugs outside of a structured trial can cloud scientific data and potentially harm patients, the WHO is working alongside the French National Agency for Research on AIDS and Viral Hepatitis (ANRS) and the Africa CDC to rapidly deploy randomized, ethical trial protocols.

By utilizing the WHO R&D Blueprint—a global framework designed to fast-track diagnostics and medicine during pandemics—authorities aim to gather definitive data on whether drugs like MBP134 or remdesivir can safely save lives. Until those trial results are finalized, the global health community must rely on vigilance, strict clinical isolation, and basic supportive care to stem the tide.

Medical Disclaimer

This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

• https://www.reuters.com/business/healthcare-pharmaceuticals/who-urges-ebola-treatments-vaccines-be-tested-only-trials-amid-bundibugyo-2026-05-28/